Travere Therapeutics, Inc.
TVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001438533
In the last 90 days, Travere Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 320 institutions reported holding it in 13F filings for Q2 2026, worth $5.98B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Travere Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 10 filings
- 9 insiders, $67.0M in total
- Insiders trading
- 9
- Net value
- −$67.0M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Travere Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Rote William E. | Chief Research Officer | 98,197 | Sep 17, 2026 | 6 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | 117,066 | Sep 17, 2026 | 7 |
| Inrig Jula | EVP, Head of R&D & CMO | 100,491 | Sep 17, 2026 | 8 |
| Reed Elizabeth E | Chief Legal Officer and GC | 105,389 | Sep 17, 2026 | 9 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | 432,886 | Sep 17, 2026 | 8 |
| Cline Christopher R. | CHIEF FINANCIAL OFFICER | 87,508 | Sep 17, 2026 | 7 |
| Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | 42,353 | Sep 17, 2026 | 6 |
| Meckler Jeffrey A | Director | 91,500 | Sep 11, 2026 | 3 |
| Lyons Gary A | Director | 61,500 | Aug 19, 2026 | 3 |
| Coughlin Timothy | Director | 56,250 | Jun 16, 2026 | 4 |
| Baynes Roy D. | Director | 41,500 | Jun 16, 2026 | 6 |
| Brinkley Ruth Williams | Director | 29,750 | May 21, 2026 | 1 |
| Squarer Ron | Director | 39,375 | May 21, 2026 | 1 |
| Orwin John A | Director | 39,375 | May 21, 2026 | 1 |
| Bruhn Suzanne Louise | Director | 32,750 | May 21, 2026 | 1 |
| Poole Sandra | Director | 34,000 | May 21, 2026 | 1 |
| Aselage Steve | Director | 146,919 | May 12, 2022 | 0 |
| Clague Laura | Chief Financial Officer | 35,655 | May 12, 2022 | 0 |
| Rosenberg Noah L. | Chief Medical Officer | 47,614 | Aug 17, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 12, 2022 (view filing) | May 11 | 1 day | Aselage SteveDirector | SSale | −2.58K | $21.92 | −$56.4K | −1.7%146.9K after | |
| Feb 11, 2022 (view filing) | Feb 10 | 1 day | Dube Eric MChief Executive Officer | SSale | −4.83K | $27.84 | −$134.5K | −2.9%159.9K after | |
| Feb 2, 2022 (view filing) | Jan 31 | 2 days | Calvin SandraVP, Corp Controller and CAO | SSale | −798 | $26.51 | −$21.2K | −2.1%36.6K after | |
| Feb 2, 2022 (view filing) | Jan 31 | 2 days | Reed Elizabeth ESVP, GC & Corporate Secretary | SSale | −1.35K | $27.40 | −$37.0K | −3.0%43.8K after | |
| Feb 2, 2022 (view filing) | Jan 31 | 2 days | Rote William E.Senior Vice President, R&D | SSale | −1.13K | $27.40 | −$30.8K | −2.4%45.2K after | |
| Feb 2, 2022 (view filing) | Jan 31 | 2 days | Heerma PeterChief Commercial Officer | SSale | −1.13K | $27.40 | −$30.8K | −1.6%67.3K after | |
| Feb 2, 2022 (view filing) | Jan 31 | 2 days | Clague LauraChief Financial Officer | SSale | −1.24K | $27.40 | −$33.9K | −3.2%37.9K after | |
| Feb 2, 2022 (view filing) | Jan 31 | 2 days | Dube Eric MChief Executive Officer | SSale | −4.81K | $27.40 | −$131.9K | −2.8%164.7K after | |
| Jan 26, 2022 (view filing) | Jan 24 | 2 days | Calvin SandraVP, Corp Controller and CAO | SSale | −934 | $24.58 | −$23.0K | −3.2%28.7K after | |
| Jan 26, 2022 (view filing) | Jan 24 | 2 days | Rote William E.Senior Vice President, R&D | SSale | −1.88K | $24.98 | −$46.8K | −4.9%36.5K after | |
| Jan 26, 2022 (view filing) | Jan 24 | 2 days | Heerma PeterChief Commercial Officer | SSale | −1.88K | $24.98 | −$46.8K | −3.1%58.6K after | |
| Jan 26, 2022 (view filing) | Jan 24 | 2 days | Reed Elizabeth ESVP, GC & Corporate Secretary | SSale | −2.25K | $24.98 | −$56.2K | −6.0%35.3K after | |
| Jan 26, 2022 (view filing) | Jan 24 | 2 days | Clague LauraChief Financial Officer | SSale | −2.06K | $24.98 | −$51.5K | −6.6%29.3K after | |
| Jan 26, 2022 (view filing) | Jan 24 | 2 days | Dube Eric MChief Executive Officer | SSale | −7.87K | $24.98 | −$196.7K | −5.6%131.7K after | |
| Jan 12, 2022 (view filing) | Jan 11 | 1 day | Reed Elizabeth ESVP, GC & Corporate Secretary | SSale | −5.00K | $27.40 | −$137.0K | −11.8%37.5K after | |
| Jan 12, 2022 (view filing) | Jan 11 | 1 day | Rote William E.Senior Vice President, R&D | SSale | −2.50K | $27.40 | −$68.5K | −6.1%38.4K after | |
| Jan 12, 2022 (view filing) | Jan 11 | 1 day | Clague LauraChief Financial Officer | SSale | −7.50K | $27.40 | −$205.5K | −19.3%31.3K after | |
| Jan 6, 2022 (view filing) | Jan 4-5 | 2 days | Dube Eric MChief Executive Officer | SSale | −17.3K | $30.08 | −$521.4K | −11.0%139.6K after | 3 lots |
| Nov 18, 2021 (view filing) | Nov 16 | 2 days | Aselage SteveDirector | SSale | −31.8K | $29.39 | −$934.6K | −17.5%149.5K after | |
| Nov 9, 2021 (view filing) | Nov 5 | 4 days | Aselage SteveDirector | SSale | −10.0K | $26.23 | −$262.3K | −5.8%161.8K after | |
| Nov 3, 2021 (view filing) | Nov 1-2 | 2 days | Aselage SteveDirector | SSale | −8.50K | $29.69 | −$252.4K | −30.4%19.5K after | 2 lots |
| Oct 8, 2021 (view filing) | Oct 7 | 1 day | Aselage SteveDirector | SSale | −60.0K | $26.25 | −$1.57M | −24.0%189.8K after | 2 lots |
| Oct 5, 2021 (view filing) | Oct 4 | 1 day | Heerma PeterChief Commercial Officer | SSale | −3.06K | $24.77 | −$75.7K | −4.8%60.5K after | |
| Aug 17, 2021 (view filing) | Aug 17 | Same day | Heerma PeterChief Commercial Officer | SSale | −1.41K | $17.12 | −$24.1K | −2.2%63.5K after | |
| Aug 17, 2021 (view filing) | Aug 17 | Same day | Dube Eric MChief Executive Officer | SSale | −7.84K | $17.12 | −$134.2K | −4.8%156.9K after | |
| Aug 17, 2021 (view filing) | Aug 17 | Same day | Rosenberg Noah L.Chief Medical Officer | SSale | −1.41K | $17.12 | −$24.1K | −2.9%47.6K after | |
| Aug 17, 2021 (view filing) | Aug 17 | Same day | Rote William E.Senior Vice President, R&D | SSale | −1.41K | $17.12 | −$24.1K | −3.8%35.7K after | |
| Aug 17, 2021 (view filing) | Aug 17 | Same day | Reed Elizabeth ESVP, GC & Corporate Secretary | SSale | −1.41K | $17.12 | −$24.1K | −3.6%37.5K after | |
| Aug 17, 2021 (view filing) | Aug 17 | Same day | Clague LauraChief Financial Officer | SSale | −1.41K | $17.12 | −$24.1K | −4.3%31.3K after | |
| Jul 29, 2021 (view filing) | Jul 28 | 1 day | Rosenberg Noah L.Chief Medical Officer | SSale | −1.25K | $13.81 | −$17.3K | −2.7%44.5K after |